Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Shengsi Biotech to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both companies to support each other and promote mutual development [1] - The partnership will focus on expanding into the restructured blood products market to better meet clinical needs and strengthen the company's product matrix [1] Group 2: Financial Overview - For the year 2024, Beida Pharmaceutical's revenue composition is projected to be 100% from pharmaceutical manufacturing [1] - As of the report date, Beida Pharmaceutical has a market capitalization of 23.9 billion yuan [1]